The Medical Letter on Drugs and Therapeutics
August 23, 2021
- In Brief: Shingrix for Immunocompromised Adults
- Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19
- Finerenone (Kerendia) for Chronic Kidney Disease
- Dasiglucagon (Zegalogue) for Severe Hypoglycemia
- Voclosporin (Lupkynis) for Lupus Nephritis
- In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)
- In Brief: A Shorter Treatment Regimen for Tuberculosis (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
In Brief: Shingrix for Immunocompromised Adults
August 23, 2021 (Issue: 1631)The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced...more
- Shingrix – an adjuvanted, recombinant herpes zoster vaccine. Med Lett Drugs Ther 2017; 59:195.
- A Bastidas et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 2019; 322:123.
- AF Dagnew et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 2019; 19:988.
- M López-Fauqued et al. Safety profile of the adjuvanted recombinant zoster vaccine in immunocompromised populations: an overview of six trials. Drug Saf 2021; 44:811.
- FDA Safety Communication. FDA requires a warning about Guillain-Barré Syndrome (GBS) be included in the prescribing information for Shingrix. March 24, 2021. Available at: https://bit.ly/3lmyvC6. Accessed August 3, 2021.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.